BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol 2014; 20(40): 14559-14567 [PMID: 25356020 DOI: 10.3748/wjg.v20.i40.14559] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 60] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Said ZNA, El-Sayed MH. Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings. World J Hepatol 2022; 14(7): 1333-1343 [DOI: 10.4254/wjh.v14.i7.1333] [Reference Citation Analysis]
2 Wu S, Yi W, Gao Y, Deng W, Bi X, Lin Y, Yang L, Lu Y, Liu R, Chang M, Shen G, Hu L, Zhang L, Li M, Xie Y. Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection. Front Immunol 2022;13:893512. [PMID: 35634301 DOI: 10.3389/fimmu.2022.893512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sampaio RMA, Dantas PEF, da Silva MIC, da Silva JR, Nunes PF, Gomes AC, Martins LC. Comparison of Patients Monoinfected with Hepatitis C Virus and Coinfected with Hepatitis B/C in the Amazon Region of Brazil. Viruses 2022;14:856. [DOI: 10.3390/v14050856] [Reference Citation Analysis]
4 Lai YR, Chang YL, Lee CH, Tsai TH, Huang KH, Lee CY. Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study. Cancers (Basel) 2022;14:583. [PMID: 35158850 DOI: 10.3390/cancers14030583] [Reference Citation Analysis]
5 Jacob R, Danta M. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34937470 DOI: 10.1080/14656566.2021.2019708] [Reference Citation Analysis]
6 de Almeida NAA, de Paula VS. Occult Hepatitis B virus (HBV) infection and challenges for hepatitis elimination: A literature review. J Appl Microbiol 2021. [PMID: 34724308 DOI: 10.1111/jam.15351] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [PMID: 34790011 DOI: 10.3748/wjg.v27.i40.6861] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rahimkhani A, Haghighat S, Noorbazargan H, Mahdavi M. Improvement of hepatitis B vaccine to induce IFN-γ cytokine response: A new formulation. Microb Pathog 2021;160:105184. [PMID: 34508828 DOI: 10.1016/j.micpath.2021.105184] [Reference Citation Analysis]
9 Gaurav A, Kapur D, Verma N, Bahadur A, Khoiwal K, Agarwal A, Kumari O, Chaturwedi J. Do Blood-Borne Viruses Affect the Progression of Labor: A Hospital-Based Pilot Study. Cureus 2021;13:e15631. [PMID: 34306843 DOI: 10.7759/cureus.15631] [Reference Citation Analysis]
10 Al-Nimer MS. Is COVID-19-induced liver injury different from other RNA viruses?‎ World J Meta-Anal 2021; 9(2): 108-127 [DOI: 10.13105/wjma.v9.i2.108] [Reference Citation Analysis]
11 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Bedi HK, Chahal D, Lowe CF, Ritchie G, Hussaini T, Marquez V, Yoshida EM. Occult Hepatitis B Reactivation after Liver Transplant: The Role of a Novel Mutation in the Surface Antigen. J Clin Transl Hepatol 2021;9:136-8. [PMID: 33604265 DOI: 10.14218/JCTH.2020.00090] [Reference Citation Analysis]
13 Jaroszewicz J, Pawłowska M, Simon K, Zarębska-Michaluk D, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Paluch K, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, Flisiak R. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Rev Anti Infect Ther 2020;18:1045-54. [PMID: 32538232 DOI: 10.1080/14787210.2020.1782189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Zarębska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M. Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther 2020;18:1033-44. [PMID: 32579414 DOI: 10.1080/14787210.2020.1776112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhu Z, Huang S, Zhang Y, Sun C, Tang Y, Zhao Q, Zhou Q, Ju W, He X. Bioinformatics analysis on multiple Gene Expression Omnibus datasets of the hepatitis B virus infection and its response to the interferon-alpha therapy. BMC Infect Dis 2020;20:84. [PMID: 31996147 DOI: 10.1186/s12879-019-4720-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Foroghi Biland L, Ferrari L, Malagnino V, Teti E, Cerva C, Gentile A, Aragri M, Salpini R, Svicher V, Andreoni M, Sarmati L. Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report. J Med Case Rep 2019;13:299. [PMID: 31542053 DOI: 10.1186/s13256-019-2232-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Desikan P, Rangnekar A, Khan Z, Panwalkar N, Bose P, Gulwani HV, Kaur S. Sero-Occurrence of HBV/HCV Co-infection and Levels of Liver Enzymes among Patients at a Tertiary Care Hospital in Central India: a Pilot Study. Cent Asian J Glob Health 2019;8:313. [PMID: 31321151 DOI: 10.5195/cajgh.2019.313] [Reference Citation Analysis]
18 Zhu S, Kahsay KM, Gui L. Knowledge, Attitudes and Practices related to standard precautions among nurses: A comparative study. J Clin Nurs 2019;28:3538-46. [PMID: 31162881 DOI: 10.1111/jocn.14945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Sayan M, Arikan A, Sanlidag T. Comparison of Performance Characteristics of DxN VERIS System versus Qiagen PCR for HBV Genotype D and HCV Genotype 1b Quantification. Pol J Microbiol 2019;68:139-43. [PMID: 31050262 DOI: 10.21307/pjm-2019-008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Wen B, Zhang J, Liu W, Tang P, Xie T, Huang L, Hu Y, Jin K, Zhang P, Liu Z, Niu L, Qu X. HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses. J Viral Hepat 2019;26:1002-10. [PMID: 30972873 DOI: 10.1111/jvh.13106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Shokri S, Mahmoudvand S, Taherkhani R, Farshadpour F, Jalalian FA. Complexity on modulation of NF-κB pathways by hepatitis B and C: A double-edged sword in hepatocarcinogenesis. J Cell Physiol 2019. [PMID: 30741410 DOI: 10.1002/jcp.28249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
22 Stournaras E, Neokosmidis G, Stogiannou D, Protopapas A, Tziomalos K. Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. Eur J Gastroenterol Hepatol 2018;30:1277-82. [PMID: 30179906 DOI: 10.1097/MEG.0000000000001254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
24 Chen ZW, Li Z, Wang QH, Wu XL, Li H, Ren H, Hu P. Large Disparity between Prevalence and Treatment Rates for Hepatitis C in Western China. J Clin Transl Hepatol 2018;6:385-90. [PMID: 30637215 DOI: 10.14218/JCTH.2018.00027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Mavilia MG, Wu GY. HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. J Clin Transl Hepatol 2018;6:296-305. [PMID: 30271742 DOI: 10.14218/JCTH.2018.00016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
26 Desikan P, Khan Z. Prevalence of hepatitis B and hepatitis C virus co-infection in India: A systematic review and meta-analysis. Indian J Med Microbiol 2017;35:332-9. [PMID: 29063876 DOI: 10.4103/ijmm.IJMM_17_257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
27 Wu Q, Li Z, Liu Q. An important role of SREBP-1 in HBV and HCV co-replication inhibition by PTEN. Virology 2018;520:94-102. [PMID: 29803738 DOI: 10.1016/j.virol.2018.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
28 Lee SW, Lee TY, Yang SS, Peng YC, Yeh HZ, Chang CS. Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals. Gastroenterology Res 2018;11:124-9. [PMID: 29707079 DOI: 10.14740/gr971w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
29 Reinhardt L, Eiffert H, Wulf G, Ströbel P, Bremer SCB, Amanzada A, Ellenrieder V, Neesse A. [Spontaneous remission of HCV infection after autologous stem cell transplantation in a 58-year-old man]. Internist (Berl) 2017;58:621-5. [PMID: 28235985 DOI: 10.1007/s00108-017-0206-3] [Reference Citation Analysis]
30 Wang XX, Pan XB, Han JC, Cong X, Jin Q, Kong XS, Wei L, Feng B. HBsAg stimulates NKG2D receptor expression on natural killer cells and inhibits hepatitis C virus replication. Hepatobiliary Pancreat Dis Int 2018;17:233-40. [PMID: 29625837 DOI: 10.1016/j.hbpd.2018.03.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
31 Preda CM, Popescu CP, Baicus C, Constantinescu I, Oproiu A, Voiosu T, Diculescu M, Negreanu L, Gheorghe L, Sporea I, Trifan A, Ceausu E, Proca D, Manuc M. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin. J Viral Hepat 2018;25:834-41. [PMID: 29397016 DOI: 10.1111/jvh.12872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Salmon D, Mondelli MU, Maticic M, Arends JE; The ESCMID Study Group for Viral Hepatitis. The benefits of hepatitis C virus cure: Every rose has thorns. J Viral Hepat 2018;25:320-8. [DOI: 10.1111/jvh.12823] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
33 Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schöneweis K, Seitz S, Tu T, Restuccia A, Frankish J, Dächert C, Schusser B, Koschny R, Polychronidis G, Schemmer P, Hoffmann K, Baumert TF, Binder M, Urban S, Bartenschlager R. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. Gastroenterology 2018;154:1791-1804.e22. [PMID: 29410097 DOI: 10.1053/j.gastro.2018.01.044] [Cited by in Crossref: 75] [Cited by in F6Publishing: 90] [Article Influence: 18.8] [Reference Citation Analysis]
34 Thibault V. Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection. Lancet Gastroenterol Hepatol 2018;3:145-7. [PMID: 29371018 DOI: 10.1016/S2468-1253(18)30004-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Al-Busafi SA, Al-Shuaili H, Omar H, Al-Zuhaibi H, Jeyaseelan L, Al-Naamani K. Epidemiology of Chronic Hepatitis C Infections at a Tertiary Care Centre in Oman. Sultan Qaboos Univ Med J 2017;17:e404-10. [PMID: 29372081 DOI: 10.18295/squmj.2017.17.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Liu J, Wu H, Chen H. Immune response to hepatitis B vaccine in patients with chronic hepatitis C infection: A systematic review and meta-analysis: Hepatitis B vaccine in chronic HCV-infected patients. Hepatol Res 2018;48:119-26. [DOI: 10.1111/hepr.13008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
37 Arora A, Singh SP, Kumar A, Saraswat VA, Aggarwal R, Bangar M, Bhaumik P, Devarbhavi H, Dhiman RK, Dixit VK, Goel A, Goswami B, Kapoor D, Madan K, Narayan J, Nijhawan S, Pandey G, Rai RR, Sahu MK, Saraf N, Shalimar, Shenoy T, Thomas V, Wadhawan M; INASL Hepatitis B Taskforce. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. J Clin Exp Hepatol 2018;8:58-80. [PMID: 29743798 DOI: 10.1016/j.jceh.2017.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
38 Liu J, Qiu S, Lu J, Yan B, Feng Y, Li L, Zhang G, Wang F, He P, Fang X, Hu Z, Liang X, Xu A, Zhang L. Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China. J Infect Dis 2017;216:327-35. [PMID: 28859430 DOI: 10.1093/infdis/jix295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
39 Marot A, Belaid A, Orlent H, Sersté T, Michielsen P, Colle I, Laleman W, de Galocsy C, Reynaert H, D'Heygere F, Moreno C, Doerig C, Henrion J, Deltenre P. Characteristics of patients with hepatitis B virus and hepatitis C virus dual infection in a Western European country: Comparison with monoinfected patients. Clin Res Hepatol Gastroenterol 2017;41:656-63. [PMID: 28867077 DOI: 10.1016/j.clinre.2017.05.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
40 Calvaruso V, Ferraro D, Licata A, Bavetta MG, Petta S, Bronte F, Colomba G, Craxì A, Di Marco V. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat 2018;25:72-9. [PMID: 28703895 DOI: 10.1111/jvh.12754] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
41 Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, Scuteri A, Vitale G, Di Donato R, Cursaro C. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J Clin Virol. 2017;93:66-70. [PMID: 28654775 DOI: 10.1016/j.jcv.2017.05.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
42 Cunha-Silva M, Marinho FRT, Oliveira PF, Lopes TM, Sevá-Pereira T, Lorena SLS, Almeida JRS. Retrospective analysis of hepatitis B virus chronic infection in 247 patients: clinical stages, response to treatment and poor prognostic factors. Braz J Infect Dis 2017;21:441-7. [PMID: 28554002 DOI: 10.1016/j.bjid.2017.03.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
43 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
44 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 2174] [Article Influence: 361.0] [Reference Citation Analysis]
45 Chen F, Zhang J, Guo F, Wen B, Luo S, Yuan D, Lin Y, Ou W, Tang P, Dai G, Li F, Liu W, Qu X. Hepatitis B, C, and D virus infection showing distinct patterns between injection drug users and the general population: Epidemic patterns of hepatitis virus. Journal of Gastroenterology and Hepatology 2017;32:515-20. [DOI: 10.1111/jgh.13460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
46 Saber MA, MM AbdelHafiz S, Khorshed FE, Aboushousha TS, Hamdy HE, Seleem MI, Soliman AH. Differential Expression of Glypican-3 and Insulin–Like Growth Factor-II mRNAs and Alpha-Fetoprotein and Ki-67 Markers in HCV Related Hepatocellular Carcinomas In Egyptian Patients. Asian Pac J Cancer Prev 2017;18:121-7. [PMID: 28240019 DOI: 10.22034/APJCP.2017.18.1.121] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
47 Chen F, Zhang J, Wen B, Luo S, Lin Y, Ou W, Guo F, Tang P, Liu W, Qu X. HBV/HCV dual infection impacts viral load, antibody response, and cytokine expression differently from HBV or HCV single infection. Sci Rep 2016;6:39409. [PMID: 28009018 DOI: 10.1038/srep39409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
48 Yan LB, Rao HY, Ma YJ, Bai L, Chen EQ, Du LY, Yang RF, Wei L, Tang H; CCgenos Study Group. Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study. BMJ Open. 2016;6:e012016. [PMID: 27733412 DOI: 10.1136/bmjopen-2016-012016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
49 Burton CE, Doucette KE, Mabilangan CA, Plitt SS, Lee BE, Preiksaitis JK. Hepatitis B and C serologic profiles of Canadian organ donors and recipients: retrospective 10-year review at a single center. Transpl Infect Dis 2016;18:520-8. [PMID: 27226204 DOI: 10.1111/tid.12558] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Sogarwal R, Madge V, Bishi P, Woleng A, Garg R. Predisposing, enabling, and need factors associated with utilization of HCV testing services among PWID in two settings in India. Hepatol Med Policy 2016;1:1. [PMID: 30288303 DOI: 10.1186/s41124-016-0010-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Gholami Parizad E, Gholami Parizad E, Khosravi A, Amraei M, Valizadeh A, Davoudian A. Comparing HBV Viral Load in Serum, Cerumen, and Saliva and Correlation With HBeAg Serum Status in Patients With Chronic Hepatitis B Infection. Hepat Mon 2016;16:e30385. [PMID: 27313632 DOI: 10.5812/hepatmon.30385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
52 Al-Mughales JA. Co-infection assessment in HBV, HCV, and HIV patients in Western Saudi Arabia. J Med Virol 2016;88:1545-51. [PMID: 26895691 DOI: 10.1002/jmv.24503] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
53 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; l’International Network on Hepatitis among Substance Users (Réseau international sur l’hépatite chez les consommateurs de drogues). Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. Int J Drug Policy 2015:S0955-3959(15)00351-5. [PMID: 26847504 DOI: 10.1016/j.drugpo.2015.11.009] [Reference Citation Analysis]
54 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; im Namen vom International Network on Hepatitis care in Substance Users. Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden. Int J Drug Policy 2015:S0955-3959(15)00352-7. [PMID: 26749563 DOI: 10.1016/j.drugpo.2015.11.010] [Reference Citation Analysis]
55 Soriano V, Labarga P, de Mendoza C, Fernández-Montero JV, Esposito I, Benítez-Gutiérrez L, Peña JM, Barreiro P. New hepatitis C therapies for special patient populations. Expert Opin Pharmacother 2016;17:217-29. [PMID: 26595348 DOI: 10.1517/14656566.2016.1112790] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
56 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ. Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. International Journal of Drug Policy 2015. [DOI: 10.1016/j.drugpo.2015.11.011] [Reference Citation Analysis]
57 Xu S, Wang Q, Zhang W, Qiu Z, Cui J, Yan W, Ni A. Seroprevalence of the Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses and Treponema pallidum at the Beijing General Hospital from 2010 to 2014: A Cross-Sectional Study. PLoS One 2015;10:e0140854. [PMID: 26502175 DOI: 10.1371/journal.pone.0140854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
58 Yu G, Chi X, Wu R, Wang X, Gao X, Kong F, Feng X, Gao Y, Huang X, Jin J, Qi Y, Tu Z, Sun B, Zhong J, Pan Y, Niu J. Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population. PLoS One 2015;10:e0139015. [PMID: 26422607 DOI: 10.1371/journal.pone.0139015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
59 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 107] [Article Influence: 14.4] [Reference Citation Analysis]
60 Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015;26:1028-38. [PMID: 26282715 DOI: 10.1016/j.drugpo.2015.07.005] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 18.1] [Reference Citation Analysis]
61 Rezaei M, Hosseini SN, Khavari-Nejad RA, Najafi F, Mahdavi M. Fast antibody responses by immuno-targeting and nanotechnology strategies versus HBsAg vaccine. Iran J Basic Med Sci 2021;24:545-50. [PMID: 34094038 DOI: 10.22038/IJBMS.2021.52715.11896] [Reference Citation Analysis]